jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Anti-CHIKUNGUNYA IgG

Bacterial/ Viral
image

Report in 4Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Detects IgG antibodies against Chikungunya virus.

1,5542,220

30% OFF

Anti-CHIKUNGUNYA IgG Test Information Guide

  • Why is it done?
    • Detects IgG antibodies against Chikungunya virus to identify past or current infection with this mosquito-borne viral pathogen
    • Confirms diagnosis in patients presenting with fever, joint pain, rash, and myalgia (muscle pain) consistent with Chikungunya infection
    • Distinguishes between acute infection (IgM positive), recent infection (IgM and IgG positive), and past/resolved infection (IgG positive only)
    • Performed in patients with epidemiological risk factors (travel to or residence in endemic areas, exposure during outbreaks)
    • Typically ordered after acute phase symptoms resolve or 1-2 weeks following symptom onset when IgG antibodies become detectable
    • Used for seroprevalence surveys and epidemiological studies to assess population immunity in endemic regions
  • Normal Range
    • Negative Result: < 1.0 Index or Ratio (may vary by laboratory); indicates no detectable IgG antibodies against Chikungunya virus
    • Positive Result: > 1.0 Index or Ratio; indicates presence of IgG antibodies suggesting past or recent infection
    • Borderline/Equivocal Result: 0.9-1.1 Index (varies by assay); may require repeat testing or confirmation with alternative method
    • Units: Index, Ratio, or S/CO (Sample-to-Cutoff) depending on assay methodology
    • Normal Interpretation: Negative results indicate no IgG antibodies detected; consistent with no prior Chikungunya infection or testing performed too early in disease course
    • Abnormal Interpretation: Positive results indicate prior Chikungunya virus infection; IgG persists lifelong and indicates immunity to reinfection
  • Interpretation
    • IgG Positive/IgM Negative: Indicates remote/past Chikungunya infection with acquired immunity; virus has been cleared from circulation
    • IgG Positive/IgM Positive: Indicates recent (within 2-4 months) or acute Chikungunya infection; patient is likely still symptomatic or recently recovered
    • IgG Negative/IgM Negative: No evidence of Chikungunya infection; may indicate testing during acute phase before antibody development or absence of infection
    • High IgG titers: May indicate more recent infection or higher viral exposure; persists for years/lifetime and does not indicate active infection
    • Factors affecting interpretation: Cross-reactivity with related alphaviruses (Ross River, O'nyong'nyong); immunocompromised status may show delayed antibody response; vaccination status if vaccine available
    • Clinical significance of paired sera: Four-fold or greater rise in IgG titer between acute and convalescent sera confirms recent infection
    • Post-infectious joint pain: Positive IgG may persist with chronic arthralgia; clinical assessment determines if ongoing symptoms warrant additional investigation
  • Associated Organs
    • Primary organ systems affected: Musculoskeletal system (joints, muscles); Dermatologic system (skin); Vascular system (blood vessels); Immune system
    • Chikungunya fever: Acute febrile illness with sudden onset fever (up to 40°C), severe polyarthralgia/polyarthritis (particularly hands, feet, knees, wrists), myalgia, and rash
    • Post-chikungunya arthralgia syndrome: Chronic joint pain persisting weeks to months or years after acute infection; affects small joints of hands/feet and larger joints
    • Rare severe complications: Hemorrhagic manifestations; neurological complications (Guillain-Barré syndrome, meningoencephalitis); cardiac involvement; particularly in neonates and elderly
    • Associated conditions with abnormal IgG results: Current or past Chikungunya infection; possible related alphavirus infections; immunological disorders affecting antibody production
    • Potential complications: Persistent arthralgia requiring long-term symptomatic management; rarely severe complications during acute phase; reduced quality of life with chronic pain
  • Follow-up Tests
    • Anti-Chikungunya IgM antibodies: Ordered alongside IgG to differentiate acute/recent infection from past infection; IgM appears earlier and disappears within weeks
    • Chikungunya virus RT-PCR: Molecular test detecting viral RNA during acute phase (first 3-5 days of illness); highest sensitivity within first week
    • Paired serum testing: Repeat IgG 2-4 weeks after initial test to assess for rising titers in recent/acute infection; four-fold rise confirms diagnosis
    • Complete blood count (CBC): May show thrombocytopenia or leukopenia during acute infection; supports clinical diagnosis
    • Liver function tests: Elevated transaminases may occur during acute phase; monitors for hepatic involvement
    • Rheumatologic workup: ESR, CRP, rheumatoid factor, anti-CCP if chronic arthralgia develops; helps differentiate from rheumatoid arthritis
    • Dengue and other arbovirus serology: Co-infections or concurrent transmission possible in endemic areas; differentiation important for management
    • Neuroimaging and CSF analysis: If neurological complications suspected (meningoencephalitis, Guillain-Barré syndrome)
    • Monitoring frequency: Single IgG positive sufficient for diagnosis of past infection; acute cases followed serially during hospitalization; chronic arthralgia may require periodic assessment
  • Fasting Required?
    • Fasting Required: No
    • Patient preparation: No fasting required; patient may eat and drink normally before blood collection
    • Medications: No medications need to be withheld; routine medications do not affect antibody test results; may continue current treatments
    • Specimen requirements: Blood serum collection via venipuncture; typically 5-10 mL in serum separator tube; stable at room temperature for 24 hours or refrigerated for several days
    • Timing considerations: Test performed any time of day; optimal timing is 1-2 weeks after symptom onset or later for IgG detection; no time restrictions for blood draw
    • Special instructions: Inform laboratory if recently vaccinated against arboviral diseases (may affect results); report recent travel to endemic areas; state relevant clinical symptoms for optimal interpretation

How our test process works!

customers
customers